Last reviewed · How we verify
Double-Stranded RNA sodium salt
Double-stranded RNA activates pattern recognition receptors on immune cells to stimulate innate and adaptive immune responses against tumors.
Double-stranded RNA activates pattern recognition receptors on immune cells to stimulate innate and adaptive immune responses against tumors. Used for Cancer immunotherapy (specific indications in phase 3 trials not publicly detailed).
At a glance
| Generic name | Double-Stranded RNA sodium salt |
|---|---|
| Also known as | RADAMIN®VIRO |
| Sponsor | Promomed, LLC |
| Drug class | Toll-like receptor agonist / Immunostimulant |
| Target | TLR3 (Toll-like receptor 3) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Double-stranded RNA (dsRNA) acts as a pathogen-associated molecular pattern (PAMP) that triggers toll-like receptors (TLRs), particularly TLR3, on dendritic cells and other immune cells. This activation promotes the production of type I interferons and pro-inflammatory cytokines, enhancing antitumor immunity and potentially synergizing with checkpoint inhibitors or other immunotherapies.
Approved indications
- Cancer immunotherapy (specific indications in phase 3 trials not publicly detailed)
Common side effects
- Flu-like symptoms
- Fever
- Fatigue
- Injection site reactions
Key clinical trials
- Study to Assess SLN124 in Patients With Polycythemia Vera (PHASE1, PHASE2)
- Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events (PHASE2)
- A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy Participants (PHASE1)
- Study for Efficacy and Safety Assessment of the Drug RADAMIN®VIRO for COVID-19 Postexposure Prophylaxis (PHASE3)
- A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine (PHASE2)
- Chemotherapeutic Agents in Brain/Breast
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Double-Stranded RNA sodium salt CI brief — competitive landscape report
- Double-Stranded RNA sodium salt updates RSS · CI watch RSS
- Promomed, LLC portfolio CI